Fluorouracil

Generic Name
Fluorouracil
Brand Names
Actikerall, Carac, Efudex, Fluoroplex, Tolak
Drug Type
Small Molecule
Chemical Formula
C4H3FN2O2
CAS Number
51-21-8
Unique Ingredient Identifier
U3P01618RT
Background

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication

For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions
Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
Associated Therapies
-
Clinical Trials
Related News

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

First Posted Date
2018-10-03
Last Posted Date
2024-07-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
35
Registration Number
NCT03693807
Locations
🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Commack, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

First Posted Date
2018-10-01
Last Posted Date
2023-06-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
8
Registration Number
NCT03690921
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

First Posted Date
2018-09-19
Last Posted Date
2023-02-16
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
92
Registration Number
NCT03678428
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

First Posted Date
2018-09-18
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1579
Registration Number
NCT03675737
Locations
🇨🇷

CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica

🇨🇷

Policlinico San Bosco ( Site 3002), San Jose, Costa Rica

🇨🇷

ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica

and more 212 locations

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

First Posted Date
2018-09-13
Last Posted Date
2021-08-24
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
215
Registration Number
NCT03668730
Locations
🇨🇳

Hai Qiang Mai, Guangzhou, Guangdong, China

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

First Posted Date
2018-09-12
Last Posted Date
2018-09-12
Lead Sponsor
University of Pisa
Target Recruit Count
120
Registration Number
NCT03668418
Locations
🇮🇹

Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

First Posted Date
2018-08-07
Last Posted Date
2023-01-06
Lead Sponsor
Mayo Clinic
Target Recruit Count
2
Registration Number
NCT03617913
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

First Posted Date
2018-08-03
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
738
Registration Number
NCT03615326
Locations
🇪🇸

Hospital Universitario Central de Asturias ( Site 1402), Oviedo, Asturias, Spain

🇺🇸

Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025), Philadelphia, Pennsylvania, United States

🇺🇸

University of Rochester ( Site 0041), Rochester, New York, United States

and more 189 locations

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

First Posted Date
2018-08-02
Last Posted Date
2023-10-03
Lead Sponsor
MedImmune LLC
Target Recruit Count
213
Registration Number
NCT03611556
Locations
🇪🇸

Research Site, Pamplona, Spain

The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer

First Posted Date
2018-07-31
Last Posted Date
2023-12-18
Lead Sponsor
Shanghai University of Traditional Chinese Medicine
Target Recruit Count
270
Registration Number
NCT03607656
Locations
🇨🇳

Longhua Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy